These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 34053589)

  • 1. Clinical Patterns of Hair Loss in Men: Is Dihydrotestosterone the Only Culprit?
    Kash N; Leavitt M; Leavitt A; Hawkins SD; Roopani RB
    Dermatol Clin; 2021 Jul; 39(3):361-370. PubMed ID: 34053589
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A review of the treatment of male pattern hair loss.
    York K; Meah N; Bhoyrul B; Sinclair R
    Expert Opin Pharmacother; 2020 Apr; 21(5):603-612. PubMed ID: 32066284
    [No Abstract]   [Full Text] [Related]  

  • 3. Assessment of the usefulness of dihydrotestosterone in the diagnostics of patients with androgenetic alopecia.
    Urysiak-Czubatka I; Kmieć ML; Broniarczyk-Dyła G
    Postepy Dermatol Alergol; 2014 Aug; 31(4):207-15. PubMed ID: 25254005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Androgen modulation of Wnt/β-catenin signaling in androgenetic alopecia.
    Premanand A; Reena Rajkumari B
    Arch Dermatol Res; 2018 Jul; 310(5):391-399. PubMed ID: 29549490
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized, double-blind controlled study of the efficacy and safety of topical solution of 0.25% finasteride admixed with 3% minoxidil vs. 3% minoxidil solution in the treatment of male androgenetic alopecia.
    Suchonwanit P; Srisuwanwattana P; Chalermroj N; Khunkhet S
    J Eur Acad Dermatol Venereol; 2018 Dec; 32(12):2257-2263. PubMed ID: 29972712
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ginsenoside F2 reduces hair loss by controlling apoptosis through the sterol regulatory element-binding protein cleavage activating protein and transforming growth factor-β pathways in a dihydrotestosterone-induced mouse model.
    Shin HS; Park SY; Hwang ES; Lee DG; Mavlonov GT; Yi TH
    Biol Pharm Bull; 2014; 37(5):755-63. PubMed ID: 24789999
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia.
    Gubelin Harcha W; Barboza Martínez J; Tsai TF; Katsuoka K; Kawashima M; Tsuboi R; Barnes A; Ferron-Brady G; Chetty D
    J Am Acad Dermatol; 2014 Mar; 70(3):489-498.e3. PubMed ID: 24411083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effectiveness of treatments for androgenetic alopecia: A systematic review and meta-analysis.
    Adil A; Godwin M
    J Am Acad Dermatol; 2017 Jul; 77(1):136-141.e5. PubMed ID: 28396101
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Psychological effect, pathophysiology, and management of androgenetic alopecia in men.
    Stough D; Stenn K; Haber R; Parsley WM; Vogel JE; Whiting DA; Washenik K
    Mayo Clin Proc; 2005 Oct; 80(10):1316-22. PubMed ID: 16212145
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dutasteride in Androgenetic Alopecia: An Update.
    Arif T; Dorjay K; Adil M; Sami M
    Curr Clin Pharmacol; 2017; 12(1):31-35. PubMed ID: 28294070
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Topical application of the Wnt/β-catenin activator methyl vanillate increases hair count and hair mass index in women with androgenetic alopecia.
    Tosti A; Zaiac MN; Canazza A; Sanchis-Gomar F; Pareja-Galeano H; Alis R; Lucia A; Emanuele E
    J Cosmet Dermatol; 2016 Dec; 15(4):469-474. PubMed ID: 27121450
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Value of hormonal levels in patients with male androgenetic alopecia treated with finasteride: better response in patients under 26 years old.
    Camacho FM; García-Hernández MJ; Fernández-Crehuet JL
    Br J Dermatol; 2008 May; 158(5):1121-4. PubMed ID: 18363752
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A mouse model of androgenetic alopecia.
    Crabtree JS; Kilbourne EJ; Peano BJ; Chippari S; Kenney T; McNally C; Wang W; Harris HA; Winneker RC; Nagpal S; Thompson CC
    Endocrinology; 2010 May; 151(5):2373-80. PubMed ID: 20233794
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Pathogenetic significance of 5-alpha reductase isoenzymes for androgenetic alopecia].
    Hoffmann R; Happle R
    Hautarzt; 1999 Mar; 50(3):165-73. PubMed ID: 10231685
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hair follicle stem cell differentiation is inhibited through cross-talk between Wnt/β-catenin and androgen signalling in dermal papilla cells from patients with androgenetic alopecia.
    Leirós GJ; Attorresi AI; Balañá ME
    Br J Dermatol; 2012 May; 166(5):1035-42. PubMed ID: 22283397
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized double-blind placebo-controlled pilot study to assess the efficacy of a 24-week topical treatment by latanoprost 0.1% on hair growth and pigmentation in healthy volunteers with androgenetic alopecia.
    Blume-Peytavi U; Lönnfors S; Hillmann K; Garcia Bartels N
    J Am Acad Dermatol; 2012 May; 66(5):794-800. PubMed ID: 21875758
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Topical fulvestrant solution has no effect on male and postmenopausal female androgenetic alopecia: results from two randomized, proof-of-concept studies.
    Gassmueller J; Hoffmann R; Webster A
    Br J Dermatol; 2008 Jan; 158(1):109-15. PubMed ID: 17986309
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A hypothetical pathogenesis model for androgenic alopecia: clarifying the dihydrotestosterone paradox and rate-limiting recovery factors.
    English RS
    Med Hypotheses; 2018 Feb; 111():73-81. PubMed ID: 29407002
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An overview of herbal alternatives in androgenetic alopecia.
    Dhariwala MY; Ravikumar P
    J Cosmet Dermatol; 2019 Aug; 18(4):966-975. PubMed ID: 30980598
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New investigational drugs for androgenetic alopecia.
    Valente Duarte de Sousa IC; Tosti A
    Expert Opin Investig Drugs; 2013 May; 22(5):573-89. PubMed ID: 23550739
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.